Maithreyi Chappidi

Maithreyi Chappidi practices at SLUCare Physician Group Dermatology Pathology in Saint Louis, Missouri.

Maithreyi Chappidi's NPI, 1710474473, was assigned on April 18, 2018. Maithreyi Chappidi holds Missouri license 2024035385.

Maithreyi Chappidi's primary practice is SLUCare Physician Group Dermatology Pathology, at 1225 S Grand Blvd, 3rd Floor, Saint Louis, MO 63104. The practice phone is (314) 617-2709.

Maithreyi Chappidi's primary practice is SLUCare Physician Group Dermatology Pathology in Saint Louis, Missouri. Maithreyi Chappidi is also affiliated with SSM Health Saint Louis University Hospital. The medical group on file is SLUCare Physician Group. Dmand AI also links Maithreyi Chappidi to 2 more hospitals, 2 medical groups, 1 clinical lab and 1 group practice or clinic, each named with a free account. Maithreyi Chappidi's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Maithreyi Chappidi practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Maithreyi Chappidi's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Maithreyi Chappidi is licensed in Missouri.

CMS data shows 13 Medicare services from Maithreyi Chappidi across 1 procedure code in 2024, for 17 Medicare patients. Medicare paid $158 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 17 Medicare patients who saw Maithreyi Chappidi in 2024. The largest group is 75 to 84, with 0 patients. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Maithreyi Chappidi's median patient age at 60, with 70% women.

In 2024, Maithreyi Chappidi wrote 237 Medicare Part D claims for 65 patients. 88% of them were for generic drugs. CMS names the drug for 110 of them, across 5 drugs with 11 or more claims each, at $91,076 in total drug cost. In 2023, CMS named 265 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Maithreyi Chappidi for performance year 2024, reported as part of a group. Maithreyi Chappidi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 37 general payments to Maithreyi Chappidi from 18 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $217. It also lists 14 research payments totaling $2,416 in 2024, naming 1 clinical trial.